Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
MNOV's Cash to Debt is ranked higher than
89% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. MNOV: No Debt )
Ranked among companies with meaningful Cash to Debt only.
MNOV' s 10-Year Cash to Debt Range
Min: 0.67  Med: 10000.00 Max: No Debt
Current: No Debt
F-Score: 2
Z-Score: -4.88
M-Score: -3.67
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -38.58
MNOV's ROE (%) is ranked lower than
56% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -30.92 vs. MNOV: -38.58 )
Ranked among companies with meaningful ROE (%) only.
MNOV' s 10-Year ROE (%) Range
Min: -788.84  Med: -57.12 Max: -19.99
Current: -38.58
-788.84
-19.99
ROA (%) -32.05
MNOV's ROA (%) is ranked lower than
55% of the 848 Companies
in the Global Biotechnology industry.

( Industry Median: -26.61 vs. MNOV: -32.05 )
Ranked among companies with meaningful ROA (%) only.
MNOV' s 10-Year ROA (%) Range
Min: -172.07  Med: -34.20 Max: -16.41
Current: -32.05
-172.07
-16.41
ROC (Joel Greenblatt) (%) -4253.52
MNOV's ROC (Joel Greenblatt) (%) is ranked lower than
78% of the 819 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. MNOV: -4253.52 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MNOV' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -39131.25  Med: -4257.63 Max: -109.01
Current: -4253.52
-39131.25
-109.01
EBITDA Growth (3Y)(%) -29.60
MNOV's EBITDA Growth (3Y)(%) is ranked lower than
81% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. MNOV: -29.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MNOV' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -83.3  Med: -29.60 Max: 188.9
Current: -29.6
-83.3
188.9
EPS Growth (3Y)(%) -31.80
MNOV's EPS Growth (3Y)(%) is ranked lower than
80% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. MNOV: -31.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MNOV' s 10-Year EPS Growth (3Y)(%) Range
Min: -86.2  Med: -26.80 Max: 254
Current: -31.8
-86.2
254
» MNOV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

MNOV Guru Trades in

Q3 2014

MNOV Guru Trades in Q3 2014

Jim Simons 49,400 sh (New)
» More
Q4 2014

MNOV Guru Trades in Q4 2014

Jim Simons 115,800 sh (+134.41%)
» More
Q1 2015

MNOV Guru Trades in Q1 2015

Jim Simons 110,800 sh (-4.32%)
» More
» Details

Insider Trades

Latest Guru Trades with MNOV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.67
MNOV's P/B is ranked higher than
50% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: 4.68 vs. MNOV: 4.67 )
Ranked among companies with meaningful P/B only.
MNOV' s 10-Year P/B Range
Min: 0.18  Med: 0.88 Max: 4.68
Current: 4.67
0.18
4.68
Current Ratio 12.12
MNOV's Current Ratio is ranked higher than
80% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.38 vs. MNOV: 12.12 )
Ranked among companies with meaningful Current Ratio only.
MNOV' s 10-Year Current Ratio Range
Min: 1.31  Med: 9.19 Max: 49.29
Current: 12.12
1.31
49.29
Quick Ratio 12.12
MNOV's Quick Ratio is ranked higher than
81% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. MNOV: 12.12 )
Ranked among companies with meaningful Quick Ratio only.
MNOV' s 10-Year Quick Ratio Range
Min: 1.31  Med: 9.19 Max: 49.29
Current: 12.12
1.31
49.29

Valuation & Return

vs
industry
vs
history
Price/Net Cash 22.33
MNOV's Price/Net Cash is ranked lower than
78% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 8.45 vs. MNOV: 22.33 )
Ranked among companies with meaningful Price/Net Cash only.
MNOV' s 10-Year Price/Net Cash Range
Min: 0.71  Med: 4.21 Max: 30.33
Current: 22.33
0.71
30.33
Price/Net Current Asset Value 16.75
MNOV's Price/Net Current Asset Value is ranked lower than
76% of the 533 Companies
in the Global Biotechnology industry.

( Industry Median: 7.60 vs. MNOV: 16.75 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
MNOV' s 10-Year Price/Net Current Asset Value Range
Min: 0.69  Med: 4.27 Max: 20.22
Current: 16.75
0.69
20.22
Price/Tangible Book 14.89
MNOV's Price/Tangible Book is ranked lower than
82% of the 683 Companies
in the Global Biotechnology industry.

( Industry Median: 5.78 vs. MNOV: 14.89 )
Ranked among companies with meaningful Price/Tangible Book only.
MNOV' s 10-Year Price/Tangible Book Range
Min: 0.4  Med: 3.13 Max: 54.67
Current: 14.89
0.4
54.67
Earnings Yield (Greenblatt) (%) -10.14
MNOV's Earnings Yield (Greenblatt) (%) is ranked lower than
63% of the 816 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. MNOV: -10.14 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MNOV' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 60.9  Med: 99.20 Max: 8448.3
Current: -10.14
60.9
8448.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NONOF, AMGN, GILD, BIIB, CELG » details
Traded in other countries:4875.Japan, RMN.Germany,
MediciNova Inc was incorporated in the State of Delaware on September 2000.It is a biopharmaceutical company focused on developing novel, small molecule therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the U.S. market. The Company operates in a single industry segment - the discovery and development of small molecule therapeutics. Its core program includes, MN-001 (NASH), MN-166 (Neurology Diseases) and MN-221 (Respiratory Diseases). Its non-core programs include, MN-001 (Bronchial Asthma), MN-001 (Interstitial Cystitis), MN-029 (Cancer) and MN-221 (Preterm Labor). The Company is subject to government regulations, in the U.S., the FDA, under the Federal Food, Drug and Cosmetic Act, as amended, and other federal statutes and regulations.
» More Articles for MNOV

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
MEDICINOVA INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial... Jul 02 2015
MediciNova Announces the Completion of Enrollment in Clinical Trial of MN-166 (ibudilast) in Alcohol... Jun 30 2015
MediciNova Announces the Completion of Enrollment in Clinical Trial of MN-166 (ibudilast) in Alcohol... Jun 30 2015
MediciNova Announces Presentation of Interim Data from Clinical Trial of MN-166 (ibudilast) in... Jun 24 2015
MediciNova Announces Presentation of Interim Data from Clinical Trial of MN-166 (ibudilast) in... Jun 24 2015
MediciNova Announces New Article Published on MN-166 (ibudilast) in Addiction Biology Jun 16 2015
MediciNova Announces New Article Published on MN-166 (ibudilast) in Addiction Biology Jun 16 2015
MEDICINOVA INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 15 2015
MediciNova Announces Randomization of 255 Subjects Completed in Phase 2b Trial of MN-166 (ibudilast)... Jun 12 2015
MediciNova Announces Randomization of 255 Subjects Completed in Phase 2b Trial of MN-166 (ibudilast)... Jun 12 2015
MediciNova Announces FDA Granted Orphan Drug Designation to MN-166 (ibudilast) for Krabbe Disease Jun 03 2015
MediciNova Announces FDA Granted Orphan Drug Designation to MN-166 (ibudilast) for Krabbe Disease Jun 03 2015
MEDICINOVA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a... May 22 2015
MEDICINOVA INC Financials May 16 2015
10-Q for MediciNova, Inc. May 13 2015
MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure May 12 2015
MEDICINOVA INC Files SEC form 10-Q, Quarterly Report May 11 2015
MediciNova Announces Full Enrollment in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS May 07 2015
MediciNova Announces Full Enrollment in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS May 07 2015
MNOV: MediciNova's Deep Pipeline Is Meaningfully Undervalued May 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK